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Purpose: MicroRNAs (miRNAs) are noncoding RNAs that play roles as tumor suppressors or 
oncogenes by regulating the expression of target genes via binding to seed-match sequences. 
Polymorphisms in the miRNA-binding site of a target gene can alter miRNA binding 
and potentially affect the risk of cancer. The objective of this study was to identify single-
nucleotide polymorphisms (SNPs) in miRNA-binding sites and assess their involvement in the 
risk of colorectal cancer (CRC).
Materials and methods: SNPs in the 3′ untranslated regions of genes were selected and 
assessed for their effects on CRC risk in Korean population using participants in Korean Cancer 
Prevention Study-II. A detailed study was carried out with the SNP rs7930 in the 3′ untranslated 
region of the translocase of outer mitochondrial membrane 20 (TOMM20) gene. A case–control 
study (1,545 controls and 620 CRC cases) was conducted to analyze the relationship between 
polymorphism at rs7930 and the risk of CRC. An interacting miRNA was predicted using web-
based software programs, and its interaction with rs7930 in CRC cell lines was investigated 
by using a luciferase assay.
Results: Individuals carrying the rs7930 AG genotype (G allele) had a 1.721-fold increased risk 
for CRC in comparison with those with the AA genotype (A allele). The miRNA miR-4273-5p 
was found to specifically interact with the A allele of rs7930 and to suppress the expression of 
the target gene (TOMM20) in CRC cell lines.
Conclusion: rs7930 is an independent genetic risk factor for CRC susceptibility. Our study 
suggests a mechanism of how this SNP contributes to CRC carcinogenesis.
Keywords: colorectal cancer, miR-4273-5p, SNP, rs7930, frequency, susceptibility
Introduction
Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause 
of cancer-related deaths, accounting for 1–2 million new cases and 600,000 deaths per 
year worldwide.1,2 Like most other cancers, no single risk factor accounts for most CRC 
cases.3,4 A significant proportion of cases are attributed to heritable genetic conditions 
that influence not only cancer susceptibility but also its clinical course.5
Single-nucleotide polymorphisms (SNPs) can be used not only as markers for 
high-throughput screening in genome-wide association studies but also as markers for 
personalized diagnosis and prediction of disease risks. Furthermore, SNPs can have 
functional consequences, thus providing a means to understand the mechanism(s) of 
how genetic factors contribute to disease development.
Functional SNPs can be found in regions where they affect gene structure or expres-
sion; such regions include coding sequences, splice junctions, 5′ and 3′ untranslated 
regions (UTRs), and promoters. SNPs located in the 3′ UTRs of the genes have recently 
attracted attention because they may affect interactions with microRNAs (miRNAs), 
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whose relationship with tumorigenesis is currently a hot 
topic of research.6,7
miRNAs affect gene expression by binding to the 3′ UTR 
of the target mRNA through a seed-match region, leading to 
translational repression or cleavage of the target mRNA. The 
same mRNA can be regulated by more than one miRNA, and 
one miRNA can target and regulate the levels of numerous 
mRNAs. Thus, functional variations such as SNPs located in 
the miRNA seed-match region can affect binding affinity of 
miRNAs to target mRNAs causing differential regulation of 
target gene expression and alter many molecular pathways 
simultaneously. As some of these pathways may be associ-
ated with tumorigenesis,8 the interaction between miRNAs 
and SNP-bearing seed-match sequences can eventually affect 
individual’s cancer risk and can be used for prognostic predic-
tion. A number of such miRNA–SNP pairs have been found 
for various cancers and some of those are as follows: pre-miR-
146a–rs2910164 for thyroid cancer;9 miR-107–rs2296616 
and miR-146a–rs2910164 for gastric cancer;10,11 miR-199a–
rs2057482 for pancreatic cancer;12 miR-196a-2–rs11614913, 
miR-520a–rs141178472, and miR-27a–rs895819 for 
CRC;13–15 miR-196a–rs11614913 for lung cancer;16 and miR-
125b–rs1434536 for breast cancer.17
In this study, we sought to find the SNPs that are 
located in the 3′ UTRs of genes and to assess their effects 
on susceptibility to CRC. Among the identified SNPs, we 
further investigated the relationship between rs7930 and 
the putative interacting miRNA miR-4273-5p. We dem-
onstrated that this SNP located in the 3′ UTR changed the 
expression of the target gene, which may affect CRC risk 
of an individual.
Materials and methods
cell culture
Human colorectal carcinoma cell lines (DLD1, HCT-116, 
SW620, SNUC4, SNUC5, and LoVo) were cultured in 
RPMI-1640 medium supplemented with 10% fetal bovine 
serum (FBS) and 100 U/mL penicillin and streptomycin. 
CCD18CO, a human colon fibroblast cell line, was cultured 
in minimum essential medium with 10% FBS and 100 U/mL 
penicillin and streptomycin. Cells were grown in a 37°C 
incubator with 5% CO
2
. The biospecimens for this study were 
provided by the Ajou Human Bio-Resource Bank, a member 
of the National Biobank of Korea, which is supported by the 
Ministry of Health and Welfare. All samples derived from 
the National Biobank of Korea were obtained with written 
informed consent under the institutional review board of each 
member of the National Biobank of Korea.
study population
The study population in the initial analysis has been described 
previously.18 Briefly it is composed of 325 patients with 
confirmed CRC from Korean Cancer Prevention study II and 
977 normal individuals as the control group. The genotypes 
of the patients and the control participants were previously 
determined using the Affymetrix Human SNP Array 5.0 
(Affymetrix, Santa Clara, CA, USA),19 and the demography 
of the study subjects have been described previously.18
For rs7930 analysis, 297 confirmed CRC patients and 
600 normal individuals were added to the already existing 
study population, resulting in a total of 620 CRC patients 
and 1,545 controls (Table S1). The cases were obtained 
from the Ajou Human Bio-Resource Bank (Suwon, Repub-
lic of Korea). CRC patients were diagnosed based on the 
International Classification of Disease for Oncology at 
Ajou Hospital. The control participants were selected 
from the Ansung–Ansan cohort study population20 of the 
Biobank for Health Science of Center for Genome Science 
in Korea National Institute of Health, and the following 
criteria were applied: 1) age between 50 and 70 years old, 
2) no past medical history of any carcinomas, and 3) no 
family history of cancers. The genotypes of the control 
participants for rs7930 were obtained from the previously 
determined genotypes using the Affymetrix Human SNP 
Array 5.0 (Affymetrix) – the same platform as in the 
initial analysis.21,22
genotyping
Genomic DNA was extracted from cells or tissues from 
CRC patients using the QIAamp DNA Mini Kit (QIAGEN, 
Valencia, CA, USA). Genomic DNA was used for genotyp-
ing of rs7930 by the SNaPshot method using SNaPshot kit 
or by sequencing using 3730XL DNA analyzer (Applied 
Biosystems, Foster City, CA, USA).
statistical analysis
The χ2 test was used to examine the differences in the dis-
tribution of genotype and allele frequencies between cases 
and controls. Hardy–Weinberg equilibrium (HWE) was 
also tested in the total study participants using χ2 analysis. 
A logistic regression analysis was used to evaluate the CRC 
risk associated with the genotype and alleles of SNPs in 
comparison to control participants. The odds ratio (OR) 
and 95% confidence intervals (CIs) of CRC associated with 
rs7930 genotype was computed and adjusted for age, sex, and 
body mass index (BMI). Missing data were present only in 
genotypes, and the individuals with missing genotypes were 
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excluded from the analysis (Table 1). We applied Bonferroni 
correction to adjust the P-values for the multiple compari-
sons in all analysis. Using the online power and sample size 
calculators (http://powerandsamplesize.com), we analyzed 
the power of this study and found that this sample size had 
power of 0.7 with χ2 test of two-sided and false discovery 
rate =0.05. Statistical analysis for the other experiments was 
carried out using a one-way analysis of variance. All tests 
were considered statistically significant at P,0.05.
construction of reporter plasmid
To construct the luciferase reporter plasmids, the full-length 
3′ UTR fragment of human TOMM20 was amplified from 
genomic DNA of AG genotype cell line because TOMM20 3′ 
UTR was contained in a single exon. The amplified fragment 
was cloned in pGEM-T easy vector (Promega Corporation, 
Fitchburg, WI, USA) and further cloned by inserting the 
fragment into psiCEHCK-2 dual luciferase vector (Promega 
Corporation) using the EcoRI restriction site. The A or G 
allele was verified by sequencing, and the A allele bearing 
construct was named psiCHECK/h_TOMM20_3′ UTR_A 
and the G allele bearing construct psiCHECK/h_TOMM20_3′ 
UTR_G. The sequences for oligonucleotides used for cloning 
are as follows: F: 5′-GGC CCT TTT CAT TGG GTA CT3′; 
R: 5′GAA AGC CCA GCT CTC TCC TT-3′. The reporter 
construct in a dual luciferase reporter vector was used for 
luciferase assay in the presence of a miR-4273-5p mimic or 
a negative control RNA.
Transfection and luciferase assay
For transfection of a reporter plasmid, cells were plated on 
a six-well plate at a density of 1.5×105 cells/well for DLD1, 
and 2×105 cells/well for HCT116, SW620, and SNUC4 
cell lines. Cells were grown overnight and transfected with 
25 nM of miRNA mimic using DharmaFECT transfection 
reagent (Thermo Fisher Scientific, Waltham, MA, USA) 
Table 1 Distribution of snP genotype and allele frequencies in crc and control participants in this study
SNP Gene Group (n) Genotype P-valuea Allele P-valuea P for 
HWEFrequency Frequency
rs8117825 ZNF831 TT Tg gg T g
control (977) 0.999 0.001 0.00001 0.999 0.001 0.00001 0.98723
case (298) 0.913 0.087 0.956 0.044 0.43104
rs4985036 ABAT gg ga aa g a
control (976) 0.985 0.015 0.00019 0.992 0.008 0.01001 0.80884
case (324) 0.957 0.043 0.978 0.022 0.69102
rs9970671 ST6GALNAC3 gg ga aa a g
control (977) 0.984 0.016 0.02682 0.988 0.012 0.56105 0.79636
case (325) 0.969 0.031 0.985 0.015 0.77819
rs16853287 SLC9A9 aa ag gg a g
control (977) 0.966 0.033 0.02379 0.983 0.017 0.07345 0.70567
case (325) 0.945 0.052 0.003 0.971 0.029 0.48802
rs7930 TOMM20 aa ag gg a g
control (945) 0.968 0.032 0.00022 0.984 0.016 0.00994 0.62002
case (323) 0.932 0.068 0.966 0.034 0.52632
rs11861556 PDP2 gg ga aa g a
control (975) 0.954 0.045 0.001 0.28339 0.976 0.024 0.04207 0.47078
case (325) 0.92 0.08 0.96 0.04 0.45256
rs17500814 ENAH aa ag gg a g
control (951) 0.975 0.024 0.001 0.00001 0.987 0.013 0.00059 0.57133
case (323) 0.926 0.074 0.963 0.037 0.72154
rs12678 PITRM1 gg ga aa g a
control (975) 0.914 0.083 0.003 0.00001 0.955 0.045 0.02063 0.42613
case (324) 0.864 0.13 0.006 0.931 0.069 0.75702
rs9129 PITRM1 gg gc cc g c
control (977) 0.916 0.083 0.003 0.00035 0.955 0.045 0.0101 0.42396
case (325) 0.862 0.132 0.006 0.928 0.072 0.80358
rs2561819 LIFR TT Ta aa T a
control (950) 0.944 0.055 0.001 0.00001 0.972 0.028 0.08849 0.7846
case (325) 0.92 0.077 0.003 0.958 0.042 0.54056
Notes: P for hWe; analysis on total study participants. aP-values adjusted for multiple comparison with Bonferroni correction. P,0.0005 was considered significant 
(α: 0.05, R: 10, r: 0). The statistical significance is denoted in bold.
Abbreviations: snP, single-nucleotide polymorphism; hWe, hardy–Weinberg equilibrium; crc, colorectal cancer.
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following the manufacturer’s instructions. After 24 hours, 
1 μg of the reporter plasmid was introduced to the cells using 
lipofectamine2000 transfection reagent (Thermo Fisher Sci-
entific). The firefly luciferase and renilla luciferase activities 
were measured at 48 hours after reporter plasmid transfection 
using the Dual-Luciferase Reporter Assay System (Promega 
Corporation) and a Luminometer (SpectraMax L, Sunnyvale, 
CA, USA). Activity of constitutive firefly luciferase in a 
separate operon served as a transfection control. The renilla 
luciferase activity was normalized against firefly luciferase 
activity. The activities are the average of three experiments 
performed in triplicates.
Western blot analysis
Cells were grown and transfected with 25 nM of miRNA 
mimic or negative control RNA using DharmaFECT reagent. 
At 72 hours after transfection, cells were harvested and 
proteins extracted using radio immunoprecipitation assay 
lysis buffer (150 mM NaCl, 1% NP-40, 0.5% Na-DCA, 
0.1% SDS, 50 mM Tris-HCl [pH 8.0], and protease inhibi-
tor) and quantified by the Bradford assay method (Quick 
Start™ Bradford Protein Assay; Bio-Rad Laboratories Inc., 
Hercules, CA, USA). Thirty micrograms of protein was 
separated on 12% SDS-polyacrylamide gel and then trans-
ferred to nitrocellulose membrane (GE Healthcare Life Sci-
ences Whatman™, Little Chalfont, Buckinghamshire, UK). 
The membrane was incubated with a mouse anti-TOMM20 
monoclonal antibody (dilution, 1:5,000, Abcam, Cambridge, 
UK), or a mouse anti-β-actin monoclonal antibody (dilution, 
1:5,000, ABM, Vancouver, BC, Canada,) overnight at 4°C 
and further incubated with a HRP-conjugated secondary 
antibody (goat anti-mouse 1:5,000, Santa Cruz Biotechnology 
Inc., Dallas, TX USA) for 1 hour at room temperature. Signals 
were detected using a enhanced chemiluminescence solution 
(Thermo Fisher Scientific). The β-actin gene (ACTB) was used 
as a loading control. The band intensity was analyzed using 
ImageJ software (version 1.49; National Institutes of Health, 
Bethesda, MD, USA) and defined as the ratio of target protein 
relative to β-actin gene.
Results
association between snPs in 3′ UTrs 
and crc
To search for SNPs associated with CRC, we selected 
SNPs located in the 3′ UTRs of genes in the Genome-Wide 
Human SNP Array 5.0 (Affymetrix), and the χ2 and logistic 
regression analyses were carried out using the genotype data 
from the Korean Cancer Prevention Study-II.23 We found 
123 SNPs in 111 genes with statistically significant OR 
(P,0.05) for CRC risk without adjustment for confound-
ing factors. Of these, the top ten risk SNPs were found in 
nine genes, which encode zinc finger protein 831 (ZNF831), 
4-aminobutyrate aminotransferase (ABAT), ST6 (α-N-acetyl-
neuraminyl-2,3-β-galactosyl-1,3)-N-acetylgalactosaminide 
α-2,6-sialyltransferase 3 (ST6GALNAC3), solute carrier 
family 9, subfamily A, member 9 (SLC9A9), translocase 
of outer mitochondrial membrane 20 (TOMM20), pyruvate 
dehydrogenase phosphatase catalytic subunit 2 (PDP2), 
enabled homologue (ENAH), pitrilysin metallopeptidase 1 
(PITRM1), and leukemia inhibitory factor receptor α (LIFR). 
With the exception of rs4985036 whose minor allele fre-
quency was 0.6%, minor allele frequencies of all the other 
SNPs were higher than 1% in the study population. All SNPs 
were in HWE in both controls and cases. The distributions 
of genotypes and allele frequency for these SNPs in the 
study population are summarized in Table 1. The genotypes 
of rs8117825, rs4985036, rs7930, rs17500814, rs12678, 
rs9129, and rs2561819 SNPs showed significant associa-
tion with CRC.
Because homozygous individuals were either not found 
or rarely present for these SNPs in the study population, 
the logistic regression analysis was performed in dominant 
model. As listed in Table 2, adjusted logistic regression 
analyses of ten SNPs showed that only six SNPs (rs8117825, 
rs7930, rs17500814, rs12678, rs9129, and rs2561819) were 
associated with elevated risk for CRC. Affected genotypes of 
six SNPs showed increased risks ranging from 30.12 to 1.262 
compared with the other homozygote genotype (Table 2). 
However, after Bonferroni correction, only rs8117825 and 
rs7930 remained significant. After adjustment for age, sex, 
and BMI (the variables that affect the risk of CRC and that hold 
in our laboratory), rs8117825 TG and GG genotype showed 
a 30-fold increased risk (95% CI: 4.22–310.2, P=0.0011) 
compared with the TT genotype. Also, the AG genotype 
of rs7930 showed a 1.72-fold increased risk for CRC (95% 
CI: 1.11–3.24, P=0.00623) compared with the AA 
genotype.
To identify miRNAs interacting with these ten SNPs, 
two online software programs (http://www.bioguo.org/
miRNASNP/ and http://compbio.uthsc.edu/miRSNP/) were 
used. Among the ten SNPs, rs8117825, rs1685328, and 
rs7930 were the only ones for which both programs predicted 
the same interacting miRNAs (Table S2). In this study, we 
focused only on rs7930 because it is located in the 3′ UTR 
of TOMM20, the role of which in tumorigenesis has not been 
studied extensively.
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Rs7930 is an independent genetic factor 
for crc risk
Initial analysis of the association of rs7930 with CRC risk was 
carried out in 323 CRC patients and 945 normal individuals 
by the χ2 test as previously reported.18 A significant associa-
tion was found between rs7930 and CRC. The frequencies 
of rs7930 AA and AG genotypes were 0.932 and 0.068 in 
CRC patients and 0.968 and 0.032 in controls, respectively 
(P=0.00022; Table 1).
Logistic regression analysis revealed that the AG and GG 
genotype was associated with a 1.721-fold increased CRC 
risk compared with the AA genotype after adjustment for 
age, sex, and BMI (95% CI: 1.11–3.24, P=0.0062; Table 2). 
There was no individual with the GG genotype in the study 
population.
We additionally analyzed 297 patients and 600 normal 
individuals to increase our confidence in this finding (thus, 
620 CRC patients and 1,545 controls were evaluated in 
total) and found similar results (Table 3). Distribution of 
the rs7930 genotypes and alleles was in HWE for both 
controls and cases. Individuals with the AG genotype had 
a 1.9-fold (95% CI: 1.191–3.034, P=0.0084) higher risk 
for CRC development after adjustment for age, sex, and 
BMI than individuals with the AA genotype. There were no 
individuals with the GG genotype in this expanded study 
population. Thus, the G allele in heterozygous individuals 
Table 2 association between crc risks and top ten high-risk snPs
SNP Gene Genotype OR (95% CI)a P-valueb
rs8117825 ZNF831 TT 1.00 0.00111
Tg 30.12 (4.22–310.2)
rs4985036 ABAT gg 1.00 0.06786
ga 3.11 (0.98–1.12)
rs9970671 ST6GALNAC3 gg 1.00 0.09259
ga 2.124 (0.99–2.48)
rs16853287 SLC9A9 aa 1.00 0.07212
ag + gg 1.997 (0.99–3.22)
rs7930 TOMM20 aa 1.00 0.00623
ag 1.721 (1.11–3.24)
rs11861556 PDP2 gg 1.00 0.05141
ga + aa 1.626 (0.97–2.18)
rs17500814 ENAH aa 1.00 0.04212
ag + gg 1.525 (1.210–2.924)
rs12678 PITRM1 gg 1.00 0.03149
ga + aa 1.493 (1.23–2.69)
rs9129 PITRM1 gg 1.00 0.04102
gc + cc 1.422 (1.21–2.65)
rs2561819 LIFR TT 1.00 0.01209
Ta + aa 1.262 (1.12–3.17)
Notes: aOr adjusted for age, sex, and BMi. bP-values adjusted for multiple comparisons with partial Bonferroni correction P,0.00629 for significance (α; 0.05, R: 10, r: 0.1, df, 1). 
The statistical significance is denoted in bold.
Abbreviations: CRC, colorectal cancer; SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval; df, degrees of freedom; BMi, body mass index.
Table 3 Distribution of genotype and allele frequencies of rs7930 in crc and control participants
Study genotype/allele Control n (%) Case n (%) P-valuea ORb 95% CI P-valuec
study set
Total 1,545 (100) 620 (100)
genotype
aa 1,502 (97.2) 588 (94.8) 0.0062 1.00 1.191–3.034 0.0084
ag 43 (2.8) 32 (5.2) 1.901
allele
a 3,047 (98.6) 1,208 (97.4) 0.0067 1.00 1.501–3.126 0.0005
g 43 (1.4) 32 (2.6) 2.535
P for hWe 0.579098 0.509512
Notes: aχ2 test. bOr adjusted for age, sex, and BMi. clogistic regression analysis. P,0.05 is considered statistically significant.
Abbreviations: CRC, colorectal cancer; OR, odds ratio; CI, confidence interval; BMI, body mass index; HWE, Hardy–Weinberg equilibrium.
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was sufficient to increase CRC susceptibility (OR =2.535, 
95% CI: 1.501–3.126, P=0.0005) after adjustment for age, 
sex, and BMI (Table 3). These results suggest that the SNP 
rs7930 is an independent genetic factor for CRC susceptibil-
ity and that G is the risk allele.
allele-dependent interaction of 
mir-4273-5p with its target
The miRNA miR-4273-5p was predicted to interact with 
rs7930 (Figure 1A). We investigated whether miR-4273-5p 
directly interacts with rs7930 using a luciferase assay in 
the CRC cell lines SW620, SNUC4, DLD1, and HCT116. 
Although the negative control RNA had no effect on 
luciferase activity regardless of the allele of the reporter 
construct, the miR-4273-5p mimic affected luciferase activity 
differently depending on the allele of the reporter construct 
(Figure 1B): the G allele plasmid had no effect, whereas the 
A allele plasmid significantly suppressed luciferase activ-
ity in comparison with the control RNA in three cell lines 
(by 60%–80%; SW620, P,0.001; DLD1, P=0.019; HCT116, 
P=0.021) and tended to decrease luciferase activity in one 
cell line (SNUC4, P=0.074).
genotype-dependent regulation of 
TOMM20 expression by mir-4273-5p 
in crc cell lines
To investigate the effect of the rs7930 genotype on the 
regulation of TOMM20 expression by miR-4273-5p, we 
first determined the rs7930 genotypes of various cell lines 
by polymerase chain reaction on genomic DNA, followed by 
sequencing. The cell lines CCD18CO, SW620, SNUC4, and 
SNUC5 had the AA genotype, whereas DLD, HCT116, and 
LoVo had the AG genotype. Unfortunately, we did not find a 
CRC cell line with the GG genotype (Table S3). TOMM20 
expression was determined at the protein level by Western 
blot analysis. The TOMM20 levels were higher in all CRC 
cell lines than in CCD18CO (Figure 2).
Regulation of TOMM20 expression by the miR-
4273-5p mimic depended on rs7930 genotype (P=0.043). 
Cell lines with the AA genotype showed a considerably 
stronger reduction in TOMM20 levels (SNUC4 and 
SNUC5, both by 60%) than those with the AG genotype 
(DLD1, by 24.3%; HCT116, 37%; LoVo, 31%) in com-
parison with the control (Figure 3A). Transfection with the 
miR-4273-5p inhibitor resulted in a more than 1.76-fold 
increase in TOMM20 expression in all CRC cell lines in 
comparison with that in cells transfected with the control 
RNA (Figure 3B).
Figure 1 a decrease in the expression of the TOMM20 a allele construct relative to 
that of the g allele construct by mir-4273-5p demonstrated by a luciferase assay.
Notes: (A) schema of mir-4273-5p selection based on interaction prediction 
using two website-based software programs. (B) relative renilla luciferase activity 
normalized against firefly luciferase activity. Each CRC cell line (SW620, SNUC4, 
DlD1, and hcT116) was transfected with the control mimic or mir-4273-5p mimic 
and then each of the reporter constructs with the g or a allele of rs7930 in the 
TOMM20 3′ UTR. A statistically significant decrease in expression was seen with 
psichecK/h_TOMM20_3′ UTr_a allele in all cell lines.
Abbreviations: TOMM20, translocate of outer mitochondria membrane; UTr, 
untranslation region; crc, colorectal cancer.
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Discussion
The SNPs and associated genes identified in this study 
may function in CRC and provide opportunities to under-
stand carcinogenesis, to develop diagnostic and prognostic 
markers, and to discover therapeutic approaches. The six risk 
SNPs in five genes we detected have not been previously 
implicated in any cancers, including CRC. However, some 
of these genes associated with high risk for CRC have been 
implicated in cancers. ENAH and LIFR have been previously 
shown to be related to CRC. Increased expression of ENAH, 
a transcriptional target of the Wnt/β-catenin pathway, was 
correlated with advanced CRC stages.24 Downregulated LIFR 
expression was shown in primary CRC tissues. Both genes 
have also been implicated in many other carcinomas such as 
myeloid leukemia or breast cancer.25–27 Therefore, the SNPs 
rs17500814 and rs2561819 can be candidate susceptibility 
markers, and interactions of the ENAH and LIFR mRNAs 
with miRNAs should be further investigated.
Although rs4985036 (in ABAT) and rs16853287 (in 
SLC9A9) were not significantly associated with CRC risk, 
nevertheless they show tendency for increased CRC risk. It is 
worthy to note that decreased ABAT expression was observed 
in breast cancer;28 SLC9A9 expression was downregulated in 
prostate cancer, and this gene was suggested as a prognostic 
marker for esophageal squamous cell cancer.29 TOMM20 is 
suggested as a prognostic marker for patients with gastric 
cancer30 and as a specific therapeutic target for anaplastic 
thyroid cancer cells.31 Therefore, the relevance of these genes 
to CRC should be established. Establishment of interactions 
of ABAT and SLC9A9 mRNAs with miRNAs may lead to 
new pairs of SNP–miRNA indicator for CRC risk. ZNF831, 
ST6GALNAC3, PDP2, and PITRM1 have not been specifi-
cally associated with any cancers. rs8117825 (in ZNF831) and 
rs12678 and rs9129 (in PITRM1) were found significantly 
associated with increased CRC risk. However, rs9970671 
(in ST6GALNAC3) and rs11861556 (in PDP2) only showed 
marginal tendency for CRC risk. Interestingly, these genes 
show variable expression in tumors (from the public data 
posted by the Broad Institute; http://firebrowse.org/). In CRC, 
the expression of ZNF831 and ST6GALNAC3 was found to 
be lower than in normal tissues (Table S4). ABAT expres-
sion was slightly decreased in colon cancer but not in rectal 
cancer, whereas the expression of SLC9A9 was markedly 
lower in CRC than in normal tissues. Therefore, the SNPs in 
these genes are attractive candidates for the development of 
biomarkers for diagnosis and prognosis of CRC. However, 
currently, the functional relevance of PITRM1 and PDP2 to 
CRC is not clear. The expression of PITRM1 was slightly 
higher (by 20%) in CRC than in normal tissues, whereas 
PDP2 expression was similar in normal and tumor tissues, 
as shown in the public data (Table S4: data from http://
firebrowse.org/). Thus, SNPs in the 3′ UTRs of these genes 
may act simply as surrogate markers of genetic contributors 
to CRC rather than play a role in CRC carcinogenesis. It may 
Figure 3 snP rs7930 variations in the TOMM20 3′ UTr affects TOMM20 expression via interaction with mir-4273-5p.
Notes: (A) regulation of the TOMM20 protein expression level according to the rs7930 genotype by mir-4273-5p in crc cell lines. (B) The level of the TOMM20 protein 
was reversed by a mir-4273-5p inhibitor.
Abbreviations: snP, single-nucleotide polymorphism; TOMM20, translocate of outer mitochondria membrane; crc, colorectal cancer; UTr, untranslation region.
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be that rs11861556 in PDP2 was not associated with CRC 
risk at all. Obviously, further study is required to understand 
their relationship (if any) to CRC.
Accumulating evidence has explained the specificity of 
miRNAs for different cancers and suggested that miRNAs 
can potentially be used as biomarkers for the diagnosis and 
prognosis of cancers. SNPs in the seed-match regions of 
miRNAs are a hot topic of research because of their potential 
usefulness as markers of noninvasiveness, their availability, 
and the ease of their detection. miRNA–SNP pairs have 
been implicated in cancer risk and suggested as prognostic 
markers. For CRC, an SNP in the let-7 miRNA-binding site 
that is present in the KRAS 3′ UTR is a prognostic biomarker, 
and rs895819 in the miR-27a binding site is associated 
with increased genetic susceptibility in Han Chinese.32,33 
rs2910164 in miR-146a binding site is associated with CRC 
susceptibility in Han Chinese,34 and rs141178472 in the 
PIK3CA 3′ UTR and miR-520a was implicated in CRC risk 
in Han Chinese population.35
This study identified rs7930–miR-4273-5p, a new SNP–
miRNA pair, as an indicator of CRC risk; this pair has never 
been studied in any cancers. Our study clearly showed that 
miR-4273-5p interacted differentially with rs7930 alleles 
and regulated expression of the target gene TOMM20 in 
CRC cells. Thus, both rs7930 and miR-4273-5p and their 
interaction itself have potential to be genetic contributors 
of CRC risks.
Our study has a few limitations. First, variables were 
limited to age, sex, and BMI, and so only limited analyses 
were possible. Since the analysis was carried out using a data 
set merged from various sources whose common variables 
were limited to age, sex, and BMI, further multivariable 
analysis was not possible. Although this presents a limitation 
for our study, the direction or the size of effect would not 
be affected considerably even if environmental factors are 
added because this study was a genetic analysis. Second, the 
power of our study is slightly less than optimal condition, 
although fairly good number of samples were analyzed. 
The sample size of our study gives the power of 0.7 with 
the genotype frequencies of controls and CRC cases, which 
warrants cautious interpretation of the results. Our study 
result suggested that individuals with the AG genotype of 
rs7930 have a 1.9-fold higher risk for CRC development. 
This OR was calculated with 95% CI of 1.19–3.03, which 
gives best guess for the size of the population effect 95% of 
time. With regard to clinical consideration, an individual with 
AG genotype may have CRC risk of anywhere between 1.19 
and 3.03, which is rather wide. Thus, a larger sample size 
is needed to obtain more reliable result with an improved 
estimate, or a narrower CI.
Since TOMM20 expression is essential for cell viability, 
it is critically important to dissect its function in CRC car-
cinogenesis. Although a rigorous validation process with a 
larger sample size must precede its application, this SNP has 
a potential to be utilized for detection of high-risk group as 
well as early detection of CRC development, which may 
provide a practical means for preventive medicine.
Conclusion
In summary, we identified SNPs that have not been previ-
ously implicated in etiology of any tumors including CRC. 
We also demonstrated that miR-4273-5p specifically inter-
acts with the A allele of the SNP rs7930, which suggests a 
mechanism for the association of the G allele (which is not 
targeted by miR-4273-5p) with an increased CRC risk. Thus, 
the A allele is protective, whereas G allele is a risk allele, 
that is, patients with the G allele have a higher risk for CRC 
development. Therefore, we provide a diagnostic biomarker 
for CRC with the rs7930 SNP_G allele. Our study found 
SNPs that may be useful for CRC risk assessment and pro-
vided opportunity to elucidate the biological importance of 
these SNPs, which may be accomplished by dissecting the 
relationship between the SNPs and miRNAs.
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Table S1 Demographic characteristics of crc and normal participants of this study
Total P-value
Normal participants
(n=1,545)
CRC patients
(n=620)
Male (n) 956 406 0.116271a
Female (n) 589 214
age (years) (± standard deviation) 60.77 (±4.77) 65.42 (±14.1) 0.042277b
BMi (kg/m2) (± standard deviation) 24.15 (±2.83) 23.20 (±3.34) 0.03692b
Notes: aχ2 test. bUnpaired t-test.
Abbreviations: BMi, body mass index; crc, colorectal cancer.
Supplementary materials
Table S2 mirnas predicted for interaction with top ten snPs associated with crc risk
SNP Gene Prediction A Prediction B
rs8117825 ZNF831 hsa-mir-3126-5p hsa-mir-337-3p hsa-mir-135a-3p
hsa-mir-337-3p
hsa-mir-7845-5p
hsa-mir-3126-5p
hsa-mir-520g-5p
hsa-mir-6873-5p
hsa-mir-6875-5p
rs4985036 ABAT
rs9970671 ST6GALNAC3 hsa-mir-3663-5p
hsa-mir-6801-5p
hsa-mir-7152-3p
hsa-mir-29b-5p
hsa-mir-329-5p
hsa-mir-4464 hsa-mir-4748
rs16853287 SLC9A9 hsa-mir-128-3p hsa-mir-140-3p hsa-mir-128-3p
hsa-mir-140-3p
hsa-mir-216a-3p
hsa-mir-3681-3p
rs7930 TOMM20 hsa-mir-4273 hsa-mir-129-5p
hsa-mir-2117
hsa-mir-375
hsa-mir-4273 hsa-mir-4677-5p
hsa-mir-6739-3p
hsa-mir-7156-5p
rs11861556 PDP2 hsa-mir-1207-3p
hsa-mir-3617-3p
hsa-mir-3927-5p
rs17500814 ENAH hsa-mir-3663-5p
rs12678 PITRM1 hsa-mir-6736-3p
rs9129 PITRM1 hsa-let-7a-5p
hsa-let-7b-5p
hsa-let-7c-5p
hsa-let-7d-5p
hsa-let-7e-5p
hsa-let-7f-5p
hsa-let-7g-5p
hsa-let-7i-5p
hsa-mir-202-3p
hsa-mir-4458
hsa-mir-4500
hsa-mir-98-5p
rs2561819 LIFR
Abbreviations: snP, single-nucleotide polymorphism; crc, colorectal cancer; mirnas, micrornas.
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Table S3 rs7930 genotypes of crc cell lines
A/A A/G G/G
ccD18cO O
colo320DM O
DlD1 O
hcT116 O
hT29 O
snUc2B O
snUc4 O
snUc5 O
sW620 O
loVo O
Abbreviation: crc, colorectal cancer.
Table S4 relative expression of the genes in crc compared to normal control tissues obtained from the gDac database
COAD READ COADREAD
Tumor (n) Normal (n) Fold change Tumor (n) Normal (n) Fold change Tumor (n) Normal (n) Fold change
ZNF831 447 41 0.303 164 10 0.274 611 51 0.299
ABAT 459 41 0.515 167 10 0.932 626 51 0.629
ST6GALNAC3 457 41 0.36 166 10 0.225 623 51 0.307
SLC9A9 457 41 0.19 167 10 0.119 624 51 0.181
PITRM1 459 41 1.21 167 10 1.21 626 51 1.2
PDP2 459 41 1.03 167 10 1.28 626 51 1.06
Abbreviations: cOaD, colon adenocarcinoma; reaD, rectum adenocarcinoma; cOaDreaD, colorectal adenocarcinoma; crc, colorectal cancer.
